PCDH9-AS1

Across TCGA pan-cancer cohorts, PCDH9-AS1 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of PCDH9-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where PCDH9-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types PCDH9-AS1 is over-expressed in tumor, although a few such as PRAD show the opposite, repressed pattern.

PRAD and LUAD are the cancer types where PCDH9-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PCDH9-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	−0.192	.028	2	view →
LUAD	All	All	+0.073	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

PCDH9-AS1–PRAD

Open the PRAD breakdown →